José Antonio Alvarez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
José Antonio Alvarez has a total of 101 co-authors. Here are the top co-authors by number of shared publications:
- Alejandro Ernesto Macías
Department of Medicine and Nutrition, University of Guanajuato, León, Guanajuato, Mexico
16 shared publications - Juan H. Macias
Universidad de Guanajuato, León, Guanajuato, México
7 shared publications Juan L. Mosqueda
Univ Guanajuato, Dept Med & Nutr, Lab Microbiol, Guanajuato, Mexico
7 shared publicationsJuan M. Muñoz
Departmento de Medicina y Nutricion, Universidad de Guanajuato, Leon, Guanajuato, Mexico
4 shared publicationsAlejandro Ernesto Macías
3 shared publicationsVirginia Arreguin
Microbiology Laboratory, Department of Medicine and Nutrition, University of Guanajuato, León, Mexico
3 shared publications
Latest Publications
- Open Access
Development and Evaluation of Antimicrobial Hospital Apparel Incorporating Copper Nanoparticles: Upscaling, Durability, and Hospital Assessment
Healthcare-associated infections (HAIs) remain a major challenge in clinical environments, where textiles frequently act as reservoirs for pathogenic bacteria. This study reports the development, upscaling, and hospital validation of antimicrobial hospital apparel incorporating copper nanoparticles (CuNPs) embedded within polyamide-6 core–sheath bicomponent filaments. A CuNP–polyamide masterbatch was produced through ultrasound-assisted melt extrusion and processed into continuous filament yarns under varying draw conditions. Filaments drawn at 1500 m/min exhibited uniform nanoparticle distribution, improved sheath exposure, and suitable mechanical properties for weaving. The optimized yarns were incorporated into woven narrow fabrics and integrated into prototype medical coats. Antimicrobial assays demonstrated >90% inhibition of S. aureus and 70% inhibition of P. aeruginosa. Durability testing showed minimal activity loss after 10 laundering cycles and no significant decline after up to 200 abrasion cycles. Cytotoxicity evaluation confirmed high fibroblast viability (97%), supporting the biocompatibility of the materials. In a hospital field trial, antimicrobial uniforms achieved substantial reductions in microbial burden, particularly at sleeve cuffs (30% total bacteria, 55% Gram-positive, 70% Gram-negative). It was demonstrated that intrinsically antimicrobial CuNP-embedded textiles offer a durable and safe strategy for reducing bacterial contamination in healthcare apparel and improving infection-control practices.
Open AccessDevelopment and Evaluation of Antimicrobial Hospital Apparel Incorporating Copper Nanoparticles: Upscaling, Durability, and Hospital Assessment
Healthcare-associated infections (HAIs) remain a major challenge in clinical environments, where textiles frequently act as reservoirs for pathogenic bacteria. This study reports the development, upscaling, and hospital validation of antimicrobial hospital apparel incorporating copper nanoparticles (CuNPs) embedded within polyamide-6 core–sheath bicomponent filaments. A CuNP–polyamide masterbatch was produced through ultrasound-assisted melt extrusion and processed into continuous filament yarns under varying draw conditions. Filaments drawn at 1500 m/min exhibited uniform nanoparticle distribution, improved sheath exposure, and suitable mechanical properties for weaving. The optimized yarns were incorporated into woven narrow fabrics and integrated into prototype medical coats. Antimicrobial assays demonstrated >90% inhibition of S. aureus and 70% inhibition of P. aeruginosa. Durability testing showed minimal activity loss after 10 laundering cycles and no significant decline after up to 200 abrasion cycles. Cytotoxicity evaluation confirmed high fibroblast viability (97%), supporting the biocompatibility of the materials. In a hospital field trial, antimicrobial uniforms achieved substantial reductions in microbial burden, particularly at sleeve cuffs (30% total bacteria, 55% Gram-positive, 70% Gram-negative). It was demonstrated that intrinsically antimicrobial CuNP-embedded textiles offer a durable and safe strategy for reducing bacterial contamination in healthcare apparel and improving infection-control practices.
- Open Access
- 21 November 2025
- Published by Sociedad Espanola de Quimioterapia
- Vol. 38 (6) , 485-494
A clinically relevant reinterpretation of disk approximation testing for inducible AmpC in Pseudomonas aeruginosa
Introduction: Current antimicrobial susceptibility methods fail to capture the variability of AmpC induction pathways in Pseudomonas aeruginosa. This leads to preventable errors in ceftazidime susceptibility reporting. We introduce a reinterpretation for the disk approximation test, based on the categorical change in ceftazidime susceptibility upon imipenem exposure. Materials and methods: A total of 73 ceftazidime-susceptible P. aeruginosa isolates were evaluated. Automated broth microdilution test was the reference standard. AmpC inducibility was conventionally defined as a ≥5 mm flattening of the ceftazidime inhibition zone adjacent to imipenem. Our novel criterion for inducibility was a change in ceftazidime category from susceptible to nonsusceptible. The probability of error in ceftazidime reporting was evaluated with three parameters. ROC curve, comparative and regression analyses were performed. Results: The reference method showed an overall error probability of 35.6%. The conventional 5 mm cutoff interpretation reduced this rate to 5.4%, but generated a significant proportion of false positives and negatives. Regression analyses showed that the flattening effect is a strong predictor of the categorical change. No association was found between basal ceftazidime susceptibility and AmpC inducibility. Conclusion: Our reinterpretation criterion for disk approximation test turns a phenotypic assay into a clinically relevant diagnostic tool to avoid errors in ceftazidime susceptibility reports. Moreover, this interpretation is readily applicable in routine microbiology laboratories, and has the potential to be directly useful for antimicrobial stewardship efforts.
- 21 November 2025
- Published by Sociedad Espanola de Quimioterapia
- Vol. 38 (6) , 485-494
Open AccessA clinically relevant reinterpretation of disk approximation testing for inducible AmpC in Pseudomonas aeruginosa
Introduction: Current antimicrobial susceptibility methods fail to capture the variability of AmpC induction pathways in Pseudomonas aeruginosa. This leads to preventable errors in ceftazidime susceptibility reporting. We introduce a reinterpretation for the disk approximation test, based on the categorical change in ceftazidime susceptibility upon imipenem exposure. Materials and methods: A total of 73 ceftazidime-susceptible P. aeruginosa isolates were evaluated. Automated broth microdilution test was the reference standard. AmpC inducibility was conventionally defined as a ≥5 mm flattening of the ceftazidime inhibition zone adjacent to imipenem. Our novel criterion for inducibility was a change in ceftazidime category from susceptible to nonsusceptible. The probability of error in ceftazidime reporting was evaluated with three parameters. ROC curve, comparative and regression analyses were performed. Results: The reference method showed an overall error probability of 35.6%. The conventional 5 mm cutoff interpretation reduced this rate to 5.4%, but generated a significant proportion of false positives and negatives. Regression analyses showed that the flattening effect is a strong predictor of the categorical change. No association was found between basal ceftazidime susceptibility and AmpC inducibility. Conclusion: Our reinterpretation criterion for disk approximation test turns a phenotypic assay into a clinically relevant diagnostic tool to avoid errors in ceftazidime susceptibility reports. Moreover, this interpretation is readily applicable in routine microbiology laboratories, and has the potential to be directly useful for antimicrobial stewardship efforts.
- Open Access
Persistence of COVID-19 Symptoms and Quality of Life at Three and Twelve Months after Hospital Discharge
Background and Objectives: Medical and public recognition of “long-COVID or post-COVID syndrome”, as well as its impact on the quality of life (QoL), is required to better address the disease burden. Objectives: We aimed to describe the persistence of COVID-19 symptoms and QoL among patients at three and twelve months after their discharge from the hospital. Materials and Methods: We conducted an observational, prospective, and longitudinal analytic study from September 2021 to April 2022. To measure QoL, we used a validated version of the 36-item Short-Form Health Survey (SF-36). Results: We included 68 patients in the study. A total of 54 (79.4%) patients reported at least one persistent symptom at three months vs. 52 (76.4%) at twelve months (p = 0.804). Some persistent symptoms (myalgia, alopecia, and cough) decreased significantly at twelve months (50% vs. 30.9%, 29.4% vs. 13.2%, and 23.5% vs. 7.4%; respectively, p = 0.007); in contrast, other persistent symptoms (sleep–wake and memory disorders) were more frequent (5.9% vs. 32.4% and 4.4% vs. 20.6%; respectively, p = ≤0.001). Regarding QoL, a statistically significant improvement was observed in some scores over time, p = ≤0.037. At twelve months, dyspnea, myalgia, and depression were risk factors associated with a poor physical component summary (PCS), p = ≤0.027, whereas anxiety, depression, and fatigue were associated with a poor mental component summary (MCS), p = ≤0.015. Conclusion: As the proportion of persistent symptoms at twelve months is high, we suggest that patients must continue under long-term follow up to reclassify, diagnose, and treat new onset symptoms/diseases.
Open AccessPersistence of COVID-19 Symptoms and Quality of Life at Three and Twelve Months after Hospital Discharge
Background and Objectives: Medical and public recognition of “long-COVID or post-COVID syndrome”, as well as its impact on the quality of life (QoL), is required to better address the disease burden. Objectives: We aimed to describe the persistence of COVID-19 symptoms and QoL among patients at three and twelve months after their discharge from the hospital. Materials and Methods: We conducted an observational, prospective, and longitudinal analytic study from September 2021 to April 2022. To measure QoL, we used a validated version of the 36-item Short-Form Health Survey (SF-36). Results: We included 68 patients in the study. A total of 54 (79.4%) patients reported at least one persistent symptom at three months vs. 52 (76.4%) at twelve months (p = 0.804). Some persistent symptoms (myalgia, alopecia, and cough) decreased significantly at twelve months (50% vs. 30.9%, 29.4% vs. 13.2%, and 23.5% vs. 7.4%; respectively, p = 0.007); in contrast, other persistent symptoms (sleep–wake and memory disorders) were more frequent (5.9% vs. 32.4% and 4.4% vs. 20.6%; respectively, p = ≤0.001). Regarding QoL, a statistically significant improvement was observed in some scores over time, p = ≤0.037. At twelve months, dyspnea, myalgia, and depression were risk factors associated with a poor physical component summary (PCS), p = ≤0.027, whereas anxiety, depression, and fatigue were associated with a poor mental component summary (MCS), p = ≤0.015. Conclusion: As the proportion of persistent symptoms at twelve months is high, we suggest that patients must continue under long-term follow up to reclassify, diagnose, and treat new onset symptoms/diseases.
- 11 July 2023
- Published by SAGE Publications in Microbial Drug Resistance
- Vol. 29 (7) , 309-315
How Does Time Affect the Antimicrobial Activity of Super-Oxidized Commercial Antiseptic Solutions? An In Vitro Test
This study aimed to identify variation in the minimum biocidal concentration (MBC) over time, comparing three commercial super-oxidized solutions with different chemical compositions. In the bactericidal assay, the following bacteria were tested: Escherichia coli (ATCC 25922), Pseudomonas aeruginosa (ATCC 27853), Staphylococcus aureus (ATCC 25923), and for each ATCC, one wild-type strain was used. In vitro experiments were performed in triplicate at 0, 60, and 120 days of follow up. A commercial formulation based on sodium and chloride ions (SCSS) was tested using a standard accelerated aging protocol. Data were analyzed with the Friedman and Wilcoxon signed-rank tests. The results showed that super-oxidized solution bases of 20 ppm of sodium (SSS) had a significant change in MBC at 120 days ( p < 0.001), whereas SCSS remained stable during the same period ( p = 0.18). However, after accelerated aging treatment, the MBC of SCSS increased ( p < 0.001). With our proposed approach, the two SSS showed MBC variation at 120 days, whereas SCSS showed stability over time, similar to chlorhexidine, but lost its bactericidal properties after accelerated aging treatment.
- 11 July 2023
- Published by SAGE Publications in Microbial Drug Resistance
- Vol. 29 (7) , 309-315
How Does Time Affect the Antimicrobial Activity of Super-Oxidized Commercial Antiseptic Solutions? An In Vitro Test
This study aimed to identify variation in the minimum biocidal concentration (MBC) over time, comparing three commercial super-oxidized solutions with different chemical compositions. In the bactericidal assay, the following bacteria were tested: Escherichia coli (ATCC 25922), Pseudomonas aeruginosa (ATCC 27853), Staphylococcus aureus (ATCC 25923), and for each ATCC, one wild-type strain was used. In vitro experiments were performed in triplicate at 0, 60, and 120 days of follow up. A commercial formulation based on sodium and chloride ions (SCSS) was tested using a standard accelerated aging protocol. Data were analyzed with the Friedman and Wilcoxon signed-rank tests. The results showed that super-oxidized solution bases of 20 ppm of sodium (SSS) had a significant change in MBC at 120 days ( p < 0.001), whereas SCSS remained stable during the same period ( p = 0.18). However, after accelerated aging treatment, the MBC of SCSS increased ( p < 0.001). With our proposed approach, the two SSS showed MBC variation at 120 days, whereas SCSS showed stability over time, similar to chlorhexidine, but lost its bactericidal properties after accelerated aging treatment.
- Open Access
- 8 July 2023
- Published by Springer Nature in BMC Oral Health
- Vol. 23 (1) , 1-8
Oral colonization by gram-negative bacilli in patients with hematologic malignancies and solid tumors compared with healthy controls
Background: Colonization of the oropharynx with gram-negative bacilli (GNB) is considered a negative prognostic factor in immunocompromised individuals. Hemato-oncologic patients represent a high-risk group due to their immunodeficiencies and associated treatments. This study aimed to determine the rates of oral colonization by GNB, associated factors, and clinical outcomes in patients with hematologic malignancies and solid tumors compared with healthy subjects. Methods: We conducted a comparative study of hemato-oncologic patients and healthy subjects from August to October 2022. Swabs were taken from the oral cavity; specimens with GNB were identified and tested for antimicrobial susceptibility. Results: We included 206 participants (103 hemato-oncologic patients and 103 healthy subjects). Hemato-oncologic patients had higher rates of oral colonization by GNB (34% vs. 17%, P = 0.007) and GNB resistant to third-generation cephalosporins (11.6% vs. 0%, P < 0.001) compared to healthy subjects. Klebsiella spp. was the predominant genus in both groups. The factor associated with oral colonization by GNB was a Charlson index ≥ 3, while ≥ 3 dental visits per year were a protective factor. Regarding colonization by resistant GNB in oncology patients, antibiotic therapy and a Charlson index ≥ 5 were identified as associated factors, while better physical functionality (ECOG ≤ 2) was associated with less colonization. Hemato-oncologic patients colonized with GNB had more 30-day infectious complications (30.5% vs. 2.9%, P = 0.0001) than non-colonized patients. Conclusion: Oral colonization by GNB and resistant GNB are prevalent in cancer patients, especially those with higher scores on the severity scales. Infectious complications occurred more frequently in colonized patients. There is a knowledge gap about dental hygiene practices in hemato-oncologic patients colonized by GNB. Our results suggest that patients’ hygienic-dietary habits, especially frequent dental visits, are a protective factor against colonization.
- 8 July 2023
- Published by Springer Nature in BMC Oral Health
- Vol. 23 (1) , 1-8
Open AccessOral colonization by gram-negative bacilli in patients with hematologic malignancies and solid tumors compared with healthy controls
Background: Colonization of the oropharynx with gram-negative bacilli (GNB) is considered a negative prognostic factor in immunocompromised individuals. Hemato-oncologic patients represent a high-risk group due to their immunodeficiencies and associated treatments. This study aimed to determine the rates of oral colonization by GNB, associated factors, and clinical outcomes in patients with hematologic malignancies and solid tumors compared with healthy subjects. Methods: We conducted a comparative study of hemato-oncologic patients and healthy subjects from August to October 2022. Swabs were taken from the oral cavity; specimens with GNB were identified and tested for antimicrobial susceptibility. Results: We included 206 participants (103 hemato-oncologic patients and 103 healthy subjects). Hemato-oncologic patients had higher rates of oral colonization by GNB (34% vs. 17%, P = 0.007) and GNB resistant to third-generation cephalosporins (11.6% vs. 0%, P < 0.001) compared to healthy subjects. Klebsiella spp. was the predominant genus in both groups. The factor associated with oral colonization by GNB was a Charlson index ≥ 3, while ≥ 3 dental visits per year were a protective factor. Regarding colonization by resistant GNB in oncology patients, antibiotic therapy and a Charlson index ≥ 5 were identified as associated factors, while better physical functionality (ECOG ≤ 2) was associated with less colonization. Hemato-oncologic patients colonized with GNB had more 30-day infectious complications (30.5% vs. 2.9%, P = 0.0001) than non-colonized patients. Conclusion: Oral colonization by GNB and resistant GNB are prevalent in cancer patients, especially those with higher scores on the severity scales. Infectious complications occurred more frequently in colonized patients. There is a knowledge gap about dental hygiene practices in hemato-oncologic patients colonized by GNB. Our results suggest that patients’ hygienic-dietary habits, especially frequent dental visits, are a protective factor against colonization.
- 5 December 2022
- Published by Elsevier in World Neurosurgery
- Vol. 170, e827-e833
Fluoroscopy-Guided Percutaneous Transpedicular Biopsy Versus Posterolateral Endoscopy for Infective Spondylodiskitis Diagnosis: A Comparative Study
- 5 December 2022
- Published by Elsevier in World Neurosurgery
- Vol. 170, e827-e833
Fluoroscopy-Guided Percutaneous Transpedicular Biopsy Versus Posterolateral Endoscopy for Infective Spondylodiskitis Diagnosis: A Comparative Study
- Open Access
Diagnostic Accuracy of the RDW for Predicting Death in COVID-19
Background and Objectives: An association between high red blood cell distribution width (RDW) and mortality has been found in several diseases, including infection and sepsis. Some studies have aimed at determining the association of elevated RDW with adverse prognosis in COVID-19, but its usefulness has not been well established. The objective of this study was to determine the accuracy of the RDW, measured at hospital admission and discharge, for predicting death in patients with COVID-19. Materials andMethods: An observational, retrospective, longitudinal, and analytical study was conducted in two different COVID-19 reference centers in the state of Guanajuato, Mexico. A total of 323 patients hospitalized by COVID-19 were included. Results: We found higher RDW levels at the time of hospital admission in the non-survivors group compared to levels in survivors (median = 13.6 vs. 13.0, p < 0.001). Final RDW levels were even higher in the deceased group when compared with those of survivors (median = 14.6 [IQR, 12.67–15.6] vs. 12.9 [IQR, 12.2–13.5], p < 0.001). For patients who died, an RDW > 14.5% was more common at the time of death than for patients who survived at the time of discharge (81 vs. 13 patients, p < 0.001; RR = 2.3, 95% CI 1.89–2.81). Conclusions: The RDW is an accessible and economical parameter that, together with other characteristics of the presentation and evolution of patients with COVID-19, can be helpful in determining the prognosis. An RDW that increases during hospitalization could be a more important mortality predictor than the RDW at hospital admission.
Open AccessDiagnostic Accuracy of the RDW for Predicting Death in COVID-19
Background and Objectives: An association between high red blood cell distribution width (RDW) and mortality has been found in several diseases, including infection and sepsis. Some studies have aimed at determining the association of elevated RDW with adverse prognosis in COVID-19, but its usefulness has not been well established. The objective of this study was to determine the accuracy of the RDW, measured at hospital admission and discharge, for predicting death in patients with COVID-19. Materials andMethods: An observational, retrospective, longitudinal, and analytical study was conducted in two different COVID-19 reference centers in the state of Guanajuato, Mexico. A total of 323 patients hospitalized by COVID-19 were included. Results: We found higher RDW levels at the time of hospital admission in the non-survivors group compared to levels in survivors (median = 13.6 vs. 13.0, p < 0.001). Final RDW levels were even higher in the deceased group when compared with those of survivors (median = 14.6 [IQR, 12.67–15.6] vs. 12.9 [IQR, 12.2–13.5], p < 0.001). For patients who died, an RDW > 14.5% was more common at the time of death than for patients who survived at the time of discharge (81 vs. 13 patients, p < 0.001; RR = 2.3, 95% CI 1.89–2.81). Conclusions: The RDW is an accessible and economical parameter that, together with other characteristics of the presentation and evolution of patients with COVID-19, can be helpful in determining the prognosis. An RDW that increases during hospitalization could be a more important mortality predictor than the RDW at hospital admission.
- Open Access
- 31 January 2022
- Published by Wiley in International Journal Of Clinical Practice
- Vol. 2022 (1) , 3757588
Efficacy of Adjuvant Tamsulosin for Improving the Stone‐Free Rate after Extracorporeal Shock Wave Lithotripsy in Renal Stones: A Randomized Controlled Trial
Introduction. Extracorporeal shock wave lithotripsy (ESWL) is an effective treatment for urolithiasis. Tamsulosin is capable of causing dilation and facilitating the migration of stones. The aim of this study is to evaluate the efficacy of adjuvant treatment with tamsulosin for improving the stone‐free rate after a single session of ESWL in the treatment of kidney stones. Methods. This is a randomized, nonplacebo‐controlled study with a sample of 60 adults with a single radiopaque kidney stone of 5–20 mm in diameter. After the ESWL session, the patients were divided into two groups. The control group received standard treatment for analgesia consisting of oral diclofenac (75 mg/12 h) as needed. The tamsulosin group received standard treatment for analgesia plus oral tamsulosin (0.4 mg/day) for eight weeks. In both groups, stone‐free status was determined using a CT scan eight weeks after ESWL. The protocol of this study was registered with ClinicalTrials.gov, identifier: NCT04819828. Results. Only 57 patients completed the study (28 tamsulosin and 29 control). Overall, the average stone diameter was 11.42 ± 4.52 mm. The stone‐free rate was 50.88% (29 of 57) overall, 53.57% (15 of 28) for the tamsulosin group, and 48.27% (14 of 29) for the control group (p = 0.680). The estimated relative risk in favor of the tamsulosin group to achieve a stone‐free status was 1.11 (95% CI 0.67–1.9). The estimated number needed to treat to achieve a single patient with renal stone‐free status after eight weeks of ESWL adjuvant treatment with tamsulosin was 19. Conclusion. Our findings suggest that tamsulosin as adjuvant treatment after a single ESWL session is well tolerated and safe, but it does not increase the stone‐free rate in patients with a single radiopaque renal stone of 5–20 mm in diameter. Our results may support the use of tamsulosin with ESWL in the case of patients with a single radiopaque renal stone of 11–20 mm in diameter based on an apparent higher stone‐free rate and a low rate of complications.
- 31 January 2022
- Published by Wiley in International Journal Of Clinical Practice
- Vol. 2022 (1) , 3757588
Open AccessEfficacy of Adjuvant Tamsulosin for Improving the Stone‐Free Rate after Extracorporeal Shock Wave Lithotripsy in Renal Stones: A Randomized Controlled Trial
Introduction. Extracorporeal shock wave lithotripsy (ESWL) is an effective treatment for urolithiasis. Tamsulosin is capable of causing dilation and facilitating the migration of stones. The aim of this study is to evaluate the efficacy of adjuvant treatment with tamsulosin for improving the stone‐free rate after a single session of ESWL in the treatment of kidney stones. Methods. This is a randomized, nonplacebo‐controlled study with a sample of 60 adults with a single radiopaque kidney stone of 5–20 mm in diameter. After the ESWL session, the patients were divided into two groups. The control group received standard treatment for analgesia consisting of oral diclofenac (75 mg/12 h) as needed. The tamsulosin group received standard treatment for analgesia plus oral tamsulosin (0.4 mg/day) for eight weeks. In both groups, stone‐free status was determined using a CT scan eight weeks after ESWL. The protocol of this study was registered with ClinicalTrials.gov, identifier: NCT04819828. Results. Only 57 patients completed the study (28 tamsulosin and 29 control). Overall, the average stone diameter was 11.42 ± 4.52 mm. The stone‐free rate was 50.88% (29 of 57) overall, 53.57% (15 of 28) for the tamsulosin group, and 48.27% (14 of 29) for the control group (p = 0.680). The estimated relative risk in favor of the tamsulosin group to achieve a stone‐free status was 1.11 (95% CI 0.67–1.9). The estimated number needed to treat to achieve a single patient with renal stone‐free status after eight weeks of ESWL adjuvant treatment with tamsulosin was 19. Conclusion. Our findings suggest that tamsulosin as adjuvant treatment after a single ESWL session is well tolerated and safe, but it does not increase the stone‐free rate in patients with a single radiopaque renal stone of 5–20 mm in diameter. Our results may support the use of tamsulosin with ESWL in the case of patients with a single radiopaque renal stone of 11–20 mm in diameter based on an apparent higher stone‐free rate and a low rate of complications.
- 25 February 2021
- Published by Instituto Mexicano del Seguro Social in Gaceta Médica de México
- Vol. 157 (1) , 113-115
¿La detección de toxinas de Clostridioides difficile es necesaria cuando se detecta la enzima glutamato deshidrogenasa?
- 25 February 2021
- Published by Instituto Mexicano del Seguro Social in Gaceta Médica de México
- Vol. 157 (1) , 113-115
¿La detección de toxinas de Clostridioides difficile es necesaria cuando se detecta la enzima glutamato deshidrogenasa?
- 1 September 2019
- Published by Elsevier in American Journal of Infection Control
- Vol. 47 (9) , e27-e29
Vancomycin-resistant Enterococcus faecium sensitivity to isopropyl alcohol before and after implementing alcohol hand rubbing in a hospital
- 1 September 2019
- Published by Elsevier in American Journal of Infection Control
- Vol. 47 (9) , e27-e29
Vancomycin-resistant Enterococcus faecium sensitivity to isopropyl alcohol before and after implementing alcohol hand rubbing in a hospital